2026

Картка пацієнта щодо безпеки застосування лікарського засобу ТЕПКІНЛІ (епкорітамаб)

Інформаційний лист-звернення до спеціалістів сфери охорони здоров’я щодо безпеки застосування лікарських засобів НОВАРИНГ®, МАРВЕЛОН®, ІМПЛАНОН® НКСТ. Лікарські засоби, що містять дезогестрел та етонгестрел: ризик менінгіоми та заходи для мінімізації ризику

Communication materials on the safe use of the medicinal product EYLEA® (aflibercept). Risk minimization in the use of the medicinal product

Educational video for doctors. The video is educational and is not used for advertising purposes. Audio version of the patient guide on the use of the medicinal product…

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product KONTROLFLEKS (tiocolchicoside). Important information on the risk of genotoxicity

Information letter-notification for healthcare professionals on the potential risk of genotoxicity (aneuploidy) with the use of tiocolchicoside, in particular embryotoxic and teratogenic effects. Contains contraindications regarding pregnancy, breastfeeding and contraception, as well as recommendations on dosage and duration of treatment. compiled automatically

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

Information letter-appeal for healthcare professionals on the safety of systemic fluoroquinolones: a reminder about restrictions on prescribing due to the risk of long-term serious adverse reactions and the procedure for reporting them. compiled automatically

Information letter-appeal to healthcare professionals regarding the medicinal product PARACETAMOL-BAXTER. Dosing tool, minimisation of the occurrence of a medication error leading to accidental overdose due to confusion between the units of measurement mg and ml

Information letter-appeal for healthcare professionals regarding the safe use of a paracetamol-based medicinal product for infusion. Contains a dosing table depending on body weight and a dose calculation tool for the purpose of minimising the risk of accidental overdose due to confusion between mg and ml. compiled automatically

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Important information on minimising the risk of aortic aneurysm and dissection and cardiac valve regurgitation/insufficiency with the use of systemic and inhaled fluoroquinolones

Information letter-appeal for healthcare professionals on the safety of systemic and inhaled fluoroquinolones: reminder of restrictions on use due to the risk of aortic aneurysm and dissection, cardiac valve regurgitation/insufficiency and other serious adverse reactions. Contains recommendations on prescribing, counselling patients and reporting adverse reactions. compiled automatically

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

Information letter-appeal for healthcare professionals on the increased risk of mortality in intensive care unit patients under 65 years of age when using dexmedetomidine, based on the results of the SPICE III study. Contains a description of the evidence, risk factors and an update to the instructions for medical use. compiled automatically

Information letter addressed to healthcare professionals regarding the medicinal product Cabazitaxel Accord (cabazitaxel). Minimizing the potential risk of medication errors resulting from confusion of the concentration of the medicinal product.

Information letter for healthcare professionals on the risk of medication errors due to confusion of concentrations of a medicinal product containing cabazitaxel. It contains recommendations on checking the product and correct dilution to avoid overdose or underdose. generated automatically

Patient card on the safe use of the medicinal product ENBREL® (etanercept)

The patient card contains information on the safe use of the medicinal product Enbrel® (etanercept), in particular on the risk of infections, the need for tuberculosis screening, and reporting of adverse reactions. Intended for patients using this medicine and their doctors. generated automatically